NOBLESVILLE, IN – A 2014 University of Rhode Island, Kingston, shows that Pomella® phenolics inhibit the formation of a biologically relevant oxidative stress marker called Advanced Glycation Endproducts, or AGE.
AGEs are formed when a sugar molecule attaches to DNA or other proteins, and prevents their proper function. Accumulation of AGE plays a key role in aging and some age-related chronic human diseases like type-2 diabetes and Alzheimer’s.
Authors stated, “Our study suggests that pomegranate may offer an attractive dietary strategy for the prevention and treatment of AGE-related diseases such as type-2 diabetes and Alzheimer’s disease.”
About Pomella®:
Patented pomegranate extract standardized to punicalagins delivering free ellagic acid in the bloodstream. Derived from pomegranates, Pomella® is a clinically researched extract. Pomella® has been found bioavailable, synergistic, and safe in published research and is analyzed with validated HPLC methodology, so you can be sure what you are getting is the same as what was used in clinical studies. Ongoing research continues to discover what Pomella® can do.
Pomella is covered under US Patents 7638640, 7897791, and 7919636.
To learn more about Pomella, please visit www.pomextract.com.
About Verdure Sciences™:
Verdure Sciences manages ingredient innovation throughout the integration of supply network, production and research platforms. With an expanding pipeline of proprietary, standardized botanical ingredients supported by pharmacokinetic, pharmacodynamic, and clinical research profiles, we work toward our unified vision to offer access to safe, effective ingredient solutions to populations worldwide.
References:
- DOI:10.1039/c4fo00538d
† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Pomella is a registered trademark of Verdure Sciences Inc. covered under US Patents 7368640, 7897791, and 7919636. All Rights Reserved. ©2014 Verdure Sciences.
